Physician profile
Eunice E Hall
NPI 1518154277
$3,526.41
in general payments reported to CMS, 2019-2025
22 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $624 · 2023: $859 · 2024: $1,217 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.83 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $683.48 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $578.40 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $292.23 | 2023-2024 | Airsupra, Tezspire, Breztri |
| Idorsia Pharmaceuticals US INC | $191.11 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $178.90 | 2022-2024 | Rexulti |
| Abbott Laboratories | $162.21 | 2024 | Infinity |
| Abbvie INC. | $137.43 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.35 | 2025 | |
| Lilly USA, LLC | $112.37 | 2022-2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $93.98 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $59.04 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $51.12 | 2023 | Trintellix |
| Hologic Sales and Service, LLC | $28.03 | 2024 | Thinprep 2000 Processor |
| Amgen INC. | $28.02 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $23.68 | 2023 | |
| Mylan Specialty L.P. | $19.71 | 2021 | |
| Merck Sharp & Dohme LLC | $15.82 | 2025 | M-M-R II, Capvaxive |
| Pfizer INC. | $15.79 | 2024 | |
| Qiagen, LLC | $15.61 | 2023 | |
| Organon LLC | $15.48 | 2023 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.